An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)
The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Mass General Brigham
-
Contact:
- Jonathan Greenberg
- Numéro de téléphone: 617-643-9402
- E-mail: MGHConcusionToolkit@partners.org
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Sustained a concussion 3-10 weeks earlier
- At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
- Age 18-35
- English fluency and literacy
- Ability and willingness to participate in study procedures, assessments, and intervention
- Access to a smartphone or computer with internet access
- Cleared for participation by clinic/study staff
Exclusion Criteria:
- Participation in mind-body or CBT treatment in the past 3 months
- Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
- Practice of mindfulness techniques > 45 minutes/week in the past 3 months
- Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
- Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
- Pregnancy
- Serious comorbidity expected to worsen in the next 6 months
- Secondary gains that may bias motivation (e.g., pending disability claim)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Toolkit for Optimal Recovery after Concussion (TOR-C)
A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills. |
TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation. |
|
Comparateur actif: Health Enhancement after Concussion (HE-C)
A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion |
HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Post-Concussion Symptom Scale (PCSS)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Generalized Anxiety Disorder scale (GAD-7)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.) |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Patient Health Questionnaire-9 (PHQ-9)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of depression symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Symptom Catastrophizing Scale
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to limit or avoid various activities in response to medical conditions |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Pittsburgh Sleep Quality Index (PSQI)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures sleep quality over the past month. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
PROMIS Cognitive Function
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Délai: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Publications générales
- Greenberg J, Singh T, Iverson GL, Silverberg ND, Macklin EA, Parker RA, Giacino JT, Yeh GY, Vranceanu AM. A Live Video Mind-Body Treatment to Prevent Persistent Symptoms Following Mild Traumatic Brain Injury: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2021 Jan 14;10(1):e25746. doi: 10.2196/25746.
- Greenberg J, Levey NS, Becker M, Yeh GY, Giacino JT, Iverson G, Silverberg ND, Parker RA, Vranceanu AM. Feasibility Randomized Controlled Trial of the Toolkit for Optimal Recovery After Concussion: A Live Video Program to Prevent Persistent Concussion Symptoms in Young Adults With Anxiety. Arch Phys Med Rehabil. 2025 Apr;106(4):527-536. doi: 10.1016/j.apmr.2024.10.011. Epub 2024 Nov 5.
- Becker ME, Stratton Levey N, Yeh GY, Giacino J, Iverson G, Silverberg N, Parker RA, McKinnon E, Siravo C, Shah P, Vranceanu AM, Greenberg J. Preliminary Feasibility of a Novel Mind-Body Program to Prevent Persistent Concussion Symptoms Among Young Adults With Anxiety: Nonrandomized Open Pilot Study. JMIR Form Res. 2024 Nov 8;8:e64540. doi: 10.2196/64540.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Lésions cérébrales, traumatiques
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Les troubles mentaux
- Blessures et Blessures
- Processus pathologiques
- Traumatisme crânio-cérébral
- Traumatisme, système nerveux
- Blessures à la tête, fermé
- Blessures non pénétrantes
- Lésions cérébrales
- Conditions pathologiques, signes et symptômes
- Troubles anxieux
- Maladie
- Commotion cérébrale
- Syndrome post-commotionnel
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2026P002591
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"
Délai de partage IPD
Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period
Critères d'accès au partage IPD
Interested parties can create an account in the Vivli Database and submit a request to access study data
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .